Ivonescimab + Cadonilimab + AK117 + Etoposide + Carboplatin (AUC 5)
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Conditions
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Trial Timeline
Oct 29, 2025 → Jun 1, 2028
NCT ID
NCT07245446About Ivonescimab + Cadonilimab + AK117 + Etoposide + Carboplatin (AUC 5)
Ivonescimab + Cadonilimab + AK117 + Etoposide + Carboplatin (AUC 5) is a phase 2 stage product being developed by Akeso for Extensive-stage Small Cell Lung Cancer (ES-SCLC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07245446. Target conditions include Extensive-stage Small Cell Lung Cancer (ES-SCLC).
What happened to similar drugs?
0 of 7 similar drugs in Extensive-stage Small Cell Lung Cancer (ES-SCLC) were approved
Approved (0) Terminated (1) Active (6)
🔄Pumitamig + Atezolizumab + Etoposide + Carboplatin (or cisplatin if carboplatin is not tolerated)Bristol Myers SquibbPhase 3
🔄BMS-986489 (BMS-986012+Nivolumab) + Atezolizumab + Carboplatin + EtoposideBristol Myers SquibbPhase 3
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07245446 | Phase 2 | Recruiting |
Competing Products
20 competing products in Extensive-stage Small Cell Lung Cancer (ES-SCLC)